Pharmafile Logo
Pharmafocus logo
Advanced Search

Ardelyx

Showing 3 posts of 3 posts found.

shutterstock_212432119

Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis

September 4, 2019
Research and Development Ardelyx, pharma, tenapanor

Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …

News
shutterstock_95714119

Strong IBS and constipation Phase 3 data sends Ardelyx shares rocketing 60%

October 12, 2017
Research and Development Ardelyx, pharma, pharmaceuticals, tenapanor

Ardelyx has confirmed that its NHE3 inhibitor tenapanor met all its primary and secondary endpoints in the study of its …

News
Astrazeneca image

AZ licences renal disease compound

October 9, 2012
Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3

AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024